Contrasting Jupiter Neurosciences (NASDAQ:JUNS) & Ovid Therapeutics (NASDAQ:OVID)

Jupiter Neurosciences (NASDAQ:JUNS) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Insider & Institutional Ownership

72.2% of Ovid Therapeutics shares are owned by institutional investors. 38.6% of Jupiter Neurosciences shares are owned by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Jupiter Neurosciences has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Jupiter Neurosciences and Ovid Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1	0	0	0	1.00
Ovid Therapeutics	1	0	10	1	2.92

Ovid Therapeutics has a consensus target price of $6.12, indicating a potential upside of 179.68%. Given Ovid Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Jupiter Neurosciences.

Profitability

This table compares Jupiter Neurosciences and Ovid Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	N/A	-246.66%
Ovid Therapeutics	N/A	-23.64%	-20.52%

Earnings & Valuation

This table compares Jupiter Neurosciences and Ovid Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20,000.00	152.88	-$8.65 million	($19.12)	-0.18
Ovid Therapeutics	$7.25 million	58.99	-$17.41 million	($0.31)	-7.06

Jupiter Neurosciences has higher earnings, but lower revenue than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Ovid Therapeutics beats Jupiter Neurosciences on 8 of the 13 factors compared between the two stocks.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.